Several biomarkers, including PD‐L1 expression [5], RNA expression signatures [6], tumor mutational burden (TMB) [7], and lymphocyte infiltration [8], have been reported as possible biomarkers to identify patients who may benefit from ICI. This evidence concerns the gene CD274 and neoplasm.